Spot on - particularly note the comment that the Melanoma...

Spot on - particularly note the comment that the Melanoma preclinical will be reported on once the patents have been lodged…..you wouldn’t bother patenting anything if the results from the trial weren’t showing favorable results.

Therefore, similar to the ccRCC results which took longer than anticipated as they were double and triple checking results, but was ultimately very successful in demonstrating synergies with existing drugs. I think it is safe to assume we may see similarly positive results next month for melanoma & ICI synergies.

We may also need to adjust our timelines for the heart safety animal data - reference to the studies being ‘complex’ and instead of reporting in early Q2, it is now just saying Q2. That’s fine and just good for us shareholders to manage expectations on timelines as we want the studies to be as through as possible to underpin BP partnership negotiations.